Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright.

BlueRock Therapeutics L.P. will lay the foundation for the German pharma's cell and gene therapy portfolio, Stefan Oelrich

Read the full 479 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers